Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 0 results

Post-approval studies (Phase 4)Study completedNCT01735955
What this trial is testing

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Who this might be right for
Chronic Myelogenous Leukemia (CML)Metastatic Gastrointestinal Stromal Tumors (GIST)Acute Lymphoblastic Leukemia (ALL)+1 more
Novartis Pharmaceuticals 57
Large-scale testing (Phase 3)Study completedNCT01511289
What this trial is testing

Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

Who this might be right for
LeukemiaLeukemia, MyeloidLeukemia, Myelogenous, Chronic, BCR-ABL Positive+3 more
Il-Yang Pharm. Co., Ltd. 242
Large-scale testing (Phase 3)Active Not RecruitingNCT04971226
What this trial is testing

Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Who this might be right for
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Novartis Pharmaceuticals 405
Large-scale testing (Phase 3)Study completedNCT01743989
What this trial is testing

Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.

Who this might be right for
Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Novartis Pharmaceuticals 620
Post-approval studies (Phase 4)Study completedNCT06427811
What this trial is testing

Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation

Who this might be right for
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Novartis Pharmaceuticals 85
Early research (Phase 1)Study completedNCT01220648
What this trial is testing

Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)

Who this might be right for
Chronic Myeloid Leukemia
Novartis Pharmaceuticals 4
Large-scale testing (Phase 3)Study completedNCT02272777
What this trial is testing

Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

Who this might be right for
Leukemia
Novartis Pharmaceuticals 225
Testing effectiveness (Phase 2)Study completedNCT01274351
What this trial is testing

Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Who this might be right for
Chronic Myelogenous Leukemia
Novartis Pharmaceuticals 112
Large-scale testing (Phase 3)Study completedNCT00006343
What this trial is testing

STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

Who this might be right for
Leukemia
Novartis
Post-approval studies (Phase 4)Study completedNCT01043874
What this trial is testing

Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response

Who this might be right for
Philadelphia Chromosome PositiveChronic Myelogenous Leukemia in Chronic Phase
Novartis Pharmaceuticals 45
Post-approval studies (Phase 4)Study completedNCT03332511
What this trial is testing

Efficacy and Safety of Nilotinib in CML-CP

Who this might be right for
Chronic Myeloid Leukemia, Chronic Phase
Seoul National University Hospital 110
Testing effectiveness (Phase 2)Ended earlyNCT00644878
What this trial is testing

Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib

Who this might be right for
Chronic Myelogenous Leukemia - Chronic Phase
Novartis Pharmaceuticals 18
Testing effectiveness (Phase 2)Study completedNCT00809211
What this trial is testing

Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Who this might be right for
Leukemia
Cancer Trials Ireland 40
Large-scale testing (Phase 3)Study completedNCT00333840
What this trial is testing

Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Who this might be right for
Chronic Myelogenous Leukemia
Novartis Pharmaceuticals 1,106